Zorbtive 和 Serostim 市場規模、佔有率和成長分析：按品牌、適應症、分銷管道、最終用戶和地區分類——2026-2033 年行業預測

2024 年全球 Zorbtive 和 Celostim 市場價值為 1.384 億美元，預計到 2033 年將從 2025 年的 1.4504 億美元成長至 2.1105 億美元，預測期（2026-2033 年）的複合年成長率為 4.8%。

Zorvtive 和 Celostim 的全球市場需求成長主要受針對肌肉萎縮和代謝紊亂的先進胜肽類療法需求的推動。 Zorvtive 是一種選擇性雄性激素受體調變器，而 Celostim 是一種獲得 FDA 批准的重組生長激素，兩者均能有效治療 HIV 相關惡病質、慢性腎臟病和老齡化肌肉減少症等疾病。隨著人們越來越依賴這些療法來取代傳統的營養和運動療法，處方量和保險覆蓋範圍也隨之激增，並促使人們轉向能夠促進瘦體重增加的生物製藥產品。保險報銷政策的改革以及新證據表明這些療法能夠降低住院率和再入院率並減少醫療保健成本，進一步推動了這個市場的發展。因此，新的適應症不斷擴展，患者群體不斷成長，生技公司和保險公司之間的合作也正在加速。

全球 Zorbtive 和 Serostim 市場的成長要素

對個人化治療方案日益成長的需求正促使醫療專業人員將Zorvtive和Celostim納入臨床實踐。臨床醫生對針對特定疾病機制的療法越來越感興趣，而這些療法的潛在益處是其廣泛採用的關鍵因素。隨著我們對各種疾病的認知不斷加深，醫生更有可能考慮為合適的患者選擇這些療法，從而導致這些療法在醫院和專科診所的使用率不斷提高。這種臨床興趣的激增不僅推動了市場的持續成長，也進一步提升了這些產品在動態治療方案製定中的重要性。

全球佐布托芬和塞洛司明市場的限制因素

由於法規核准流程嚴苛，要求生產商提供大量文件和臨床檢驗，全球佐布替尼類藥物和血清素類藥物市場面臨許多限制因素。監管機構要求提供詳細的安全性和有效性信息，這延長了研發週期並增加了成本。此外，需要提交多項申請以及潛在的上市後義務進一步加劇了企業的不確定性，阻礙了其快速進入市場。這些繁瑣的核准流程阻礙了產品的供應，限制了市場競爭，並延緩了新配方藥物的上市，最終抑制了整體市場成長。此外，這些延誤還會削弱投資者信心，可能導致創新研發專案的資金減少。

全球 Zorbtive 和 Serostim 市場趨勢

Zorvtive 和 Celostim 市場正經歷著向個人化給藥平台的顯著轉變，該平台優先考慮為每位患者提供個人化護理。臨床醫生擴大利用精準給藥技術，將藥理基因組學見解與即時治療監測相結合，以最佳化治療方案。這一趨勢正在提高患者依從性，最大限度地減少副作用，並提升醫療服務提供者對這些療法的接受度。同時，製造商正在加大對數位健康創新的投入，與診斷公司建立策略合作夥伴關係，並推出可簡化門診劑量調整的軟體試劑盒。這些發展共同建構了一種數據驅動、以患者為中心的模式，為在全球範圍內改善醫療保健效果鋪平了道路。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球 Zorbtive 和 Serostim 市場規模：按品牌分類

• Zorbtive
• Serostim

Zorbtive 與 Serostim 的全球市場規模（依適應症分類）：

• 短腸症候群
• 與愛滋病毒相關的消瘦

Zorbtive 和 Serostim 的全球市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

Zorbtive 和 Serostim 的全球市場規模：按最終用戶分類

• 醫院
• 專科診所
• 居家照護

全球 Zorbtive 和 Serostim 市場規模：按地區分類

• 北美洲
• 歐洲
• 亞太地區
• 世界其他地區

全球Zorbtive與Serostim市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• EMD Serono, Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Ipsen SA
• Ascendis Pharma A/S
• Sandoz Group AG
• GeneScience Pharmaceuticals Co., Ltd.
• AnkeBio Co., Ltd.
• Genexine, Inc.
• LG Chem Ltd.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Dr. Reddy's Laboratories Limited
• Ferring Pharmaceuticals
• Amgen Inc.
• BioPartners GmbH
• Hybio Pharmaceutical Co., Ltd.

結論與建議

Global Zorbtive or Serostim Market size was valued at USD 138.4 Million in 2024 and is poised to grow from USD 145.04 Million in 2025 to USD 211.05 Million by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

The global market for Zorbtive and Serostim is driven by the rising need for advanced peptide therapeutics targeting muscle wasting and metabolic disorders. Both Zorbtive, a selective androgen receptor modulator, and Serostim, an FDA-approved recombinant growth hormone, effectively address conditions like HIV-related cachexia, chronic kidney disease, and age-related sarcopenia. Increased reliance on these therapies over traditional nutrition and exercise has led to a surge in prescriptions and reimbursement coverage, marking a shift towards biologics that promote lean body mass gains. This market is further bolstered by reform in reimbursement policies and emerging evidence linking these therapies to lower hospital readmissions and healthcare costs. As such, new indications are developing, enhancing the patient demographic and fostering collaborations between biotech firms and payers.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Zorbtive or Serostim market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Zorbtive or Serostim Market Segments Analysis

Global zorbtive or serostim market is segmented by brand, indication, distribution channel, end user and region. Based on brand, the market is segmented into Zorbtive and Serostim. Based on indication, the market is segmented into Short Bowel Syndrome and HIV-Associated Wasting. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Zorbtive or Serostim Market

The growing preference for personalized treatment solutions is motivating healthcare professionals to integrate Zorbtive and Serostim into their therapeutic practices. Clinicians are increasingly drawn to treatments that target specific disease mechanisms, with the potential benefits of these therapies being a key factor in their adoption. As understanding of various diseases expands, physicians are more likely to evaluate these options for suitable patients, leading to increased utilization in hospitals and specialized clinics. This surge in clinical interest not only contributes to ongoing market growth but also strengthens the significance of these products in the dynamic landscape of therapy planning.

Restraints in the Global Zorbtive or Serostim Market

The global market for Zorbtive and Serostim faces significant constraints due to rigorous regulatory approval processes that require manufacturers to provide extensive documentation and clinical validation. Regulatory agencies expect detailed safety and efficacy information, which prolongs development timelines and increases costs. The need for multiple submissions and possible post-marketing obligations adds to the uncertainty companies face, impeding swift market entry. These bureaucratic challenges hinder product availability and limit competition, ultimately restraining overall market growth by slowing the introduction of new formulations to patients. Additionally, such delays can diminish investor confidence, resulting in reduced funding for innovative development projects.

Market Trends of the Global Zorbtive or Serostim Market

The market for Zorbtive and Serostim is experiencing a significant shift towards personalized dosing platforms that prioritize individualized patient care. Clinicians are increasingly leveraging precision dosing technologies that merge pharmacogenomic insights with real-time therapeutic monitoring to optimize treatment plans. This trend enhances patient adherence, minimizes adverse effects, and boosts acceptance of these therapies among specialty care providers. In tandem, manufacturers are channeling resources into digital health innovations, forming strategic partnerships with diagnostic companies, and introducing software-enabled kits to streamline dosing adjustments in outpatient care. Collectively, these developments are establishing a data-driven, patient-centric approach, paving the way for improved health outcomes on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Zorbtive Or Serostim Market Size by Brand & CAGR (2026-2033)

• Market Overview
• Zorbtive
• Serostim

Global Zorbtive Or Serostim Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Short Bowel Syndrome
• HIV-Associated Wasting

Global Zorbtive Or Serostim Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Zorbtive Or Serostim Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare

Global Zorbtive Or Serostim Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific
• Rest of the World

Global Zorbtive Or Serostim Market Size & CAGR (2026-2033)

• North America (Brand, Indication, Distribution Channel, End User, Region)
  • US
  • Canada
• Europe (Brand, Indication, Distribution Channel, End User, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Brand, Indication, Distribution Channel, End User, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Brand, Indication, Distribution Channel, End User, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Brand, Indication, Distribution Channel, End User, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• EMD Serono, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascendis Pharma A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneScience Pharmaceuticals Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AnkeBio Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genexine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioPartners GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hybio Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations